Brief: Vaxart Provides Business Update And Full Year 2022 Financial Results
15/03/2023 20:05
March 15 (Reuters) -
* VAXART PROVIDES BUSINESS UPDATE AND FULL YEAR 2022
FINANCIAL
RESULTS
* VAXART INC - PORTFOLIO PRIORITIZATION EXTENDS CASH RUNWAY
INTO
Q2 2024
* VAXART INC - REPORT TOPLINE DATA FROM ONGOING PHASE 2
CHALLENGE
STUDY OF VAXART'S MONOVALENT NOROVIRUS VACCINE CANDIDATE IN Q3
2023
* VAXART INC - REPORT TOPLINE DATA FROM ONGOING PHASE 2
DOSE-RANGING STUDY OF VAXART'S BIVALENT NOROVIRUS VACCINE
CANDIDATE IN MID-2023
Source text for Eikon: ID:nGNXblvJyM
Further company coverage: VXRT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts